Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71]
Year: 2018
Type: erratum
Source: European Urology
Authors: Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer
Institutions: Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Roswell Park Comprehensive Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Stanford Cancer Institute, University of Washington, Fred Hutch Cancer Center, Vanderbilt University Medical Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Fox Chase Cancer Center, Hospital Universitario 12 De Octubre, Westmead Hospital, Aarhus University Hospital, Helsinki University Hospital, Swansea University, Essen University Hospital, University of Duisburg-Essen, Chiba Cancer Center, Bristol-Myers Squibb (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2782455519